50-60 Hz magnetic fields and cancer, forty years of research: it is time to reassure

In 1979, an epidemiological study carried out in Denver, Colorado first suggested that very weak alternating magnetic fields arising from electrical lines around houses was associated with an increased risk of cancer in children. The potential impact on public health was high, considering the fact that exposure to power-frequency magnetic fields is omnipresent. All power transmission and distribution networks, domestic and industrial wiring, and all kinds of electrical equipment give off magnetic fields. The hypothesis was taken seriously and substantial research budgets have been devoted not only to answering the important question raised by this study but more broadly to identify all other potential health effects of magnetic fields. Since 1979, an exceptional number of scientific studies have been published worldwide. In 2007, the World Health Organization published one of the most comprehensive review so far. The present article summarizes important facts regarding the interaction between a magnetic field and the human body and the key findings from this extensive research looking for a possible link with cancer.Instituto de Investigaciones Tecnológicas para Redes y Equipos Eléctrico

Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals

CD163, a haptoglobin-hemoglobin (Hp-Hb) scavenger receptor, expressed by monocytes and macrophages, is important in resolution of inflammation. Age-related non-AIDS co-morbidities in HIV-infected individuals, particularly dementia and cardiovascular disease, result in part from effects of HIV-1 infection on monocyte and macrophage biology. CD163 co-expression on CD14+CD16++ monocytes has been proposed as a useful biomarker for HIV-1 disease progression and the presence of HIV associated dementia. Here we investigated CD163 expression on monocyte subsets ex vivo, on cultured macrophages, and soluble in plasma, in the setting of HIV-1 infection. Whole blood immunophenotyping revealed CD163 expression on CD14++CD16- monocytes but not on CD14+CD16++ monocytes (P = 0.004), supported by CD163 mRNA levels. Incubation with M-CSF induced CD163 protein expression on CD14+CD16++ monocytes to the same extent as CD14++CD16− monocytes. CD163 expression on CD14++CD16+ monocytes from HIV-infected subjects was significantly higher than from uninfected individuals, with a trend towards increased expression on CD14++CD16− monocytes (P = 0.019 and 0.069 respectively), which is accounted for by HIV-1 therapy including protease inhibitors. Shedding of CD163 was shown to predominantly occur from the CD14++CD16− subset after Ficoll isolation and LPS stimulation. Soluble CD163 concentration in plasma from HIV-1 infected donors was similar to HIV-1 uninfected donors. Monocyte CD163 expression in HIV-1 infected patients showed a complicated relationship with classical measures of disease progression. Our findings clarify technical issues regarding CD163 expression on monocyte subsets and further elucidates its role in HIV-associated inflammation by demonstrating that CD163 is readily lost from CD14++CD16− monocytes and induced in pro-inflammatory CD14+CD16++ monocytes by M-CSF. Our data show that all monocyte subsets are potentially capable of differentiating into CD163-expressing anti-inflammatory macrophages given appropriate stimuli. Levels of CD163 expression on monocytes may be a potential biomarker reflecting efforts by the immune system to resolve immune activation and inflammation in HIV-infected individuals

Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals

CD163, a haptoglobin-hemoglobin (Hp-Hb) scavenger receptor, expressed by monocytes and macrophages, is important in resolution of inflammation. Age-related non-AIDS co-morbidities in HIV-infected individuals, particularly dementia and cardiovascular disease, result in part from effects of HIV-1 infection on monocyte and macrophage biology. CD163 co-expression on CD14+CD16++ monocytes has been proposed as a useful biomarker for HIV-1 disease progression and the presence of HIV associated dementia. Here we investigated CD163 expression on monocyte subsets ex vivo, on cultured macrophages, and soluble in plasma, in the setting of HIV-1 infection. Whole blood immunophenotyping revealed CD163 expression on CD14++CD16- monocytes but not on CD14+CD16++ monocytes (P = 0.004), supported by CD163 mRNA levels. Incubation with M-CSF induced CD163 protein expression on CD14+CD16++ monocytes to the same extent as CD14++CD16− monocytes. CD163 expression on CD14++CD16+ monocytes from HIV-infected subjects was significantly higher than from uninfected individuals, with a trend towards increased expression on CD14++CD16− monocytes (P = 0.019 and 0.069 respectively), which is accounted for by HIV-1 therapy including protease inhibitors. Shedding of CD163 was shown to predominantly occur from the CD14++CD16− subset after Ficoll isolation and LPS stimulation. Soluble CD163 concentration in plasma from HIV-1 infected donors was similar to HIV-1 uninfected donors. Monocyte CD163 expression in HIV-1 infected patients showed a complicated relationship with classical measures of disease progression. Our findings clarify technical issues regarding CD163 expression on monocyte subsets and further elucidates its role in HIV-associated inflammation by demonstrating that CD163 is readily lost from CD14++CD16− monocytes and induced in pro-inflammatory CD14+CD16++ monocytes by M-CSF. Our data show that all monocyte subsets are potentially capable of differentiating into CD163-expressing anti-inflammatory macrophages given appropriate stimuli. Levels of CD163 expression on monocytes may be a potential biomarker reflecting efforts by the immune system to resolve immune activation and inflammation in HIV-infected individuals

Motivational modulation of bradykinesia in Parkinson's disease off and on dopaminergic medication.

Motivational influence on bradykinesia in Parkinson's disease may be observed in situations of emotional and physical stress, a phenomenon known as paradoxical kinesis. However, little is known about motivational modulation of movement speed beyond these extreme circumstances. In particular, it is not known if motivational factors affect movement speed by improving movement preparation/initiation or execution (or both) and how this effect relates to the patients' medication state. In the present study, we tested if provision of motivational incentive through monetary reward would speed-up movement initiation and/or execution in Parkinson's disease patients and if this effect depended on dopaminergic medication. We studied the effect of monetary incentive on simple reaction time in 11 Parkinson's disease patients both "off" and "on" dopaminergic medication and in 11 healthy participants. The simple reaction time task was performed across unrewarded and rewarded blocks. The initiation time and movement time were quantified separately. Anticipation errors and long responses were also recorded. The prospect of reward improved initiation times in Parkinson's disease patients both "off" and "on" dopaminergic medication, to a similar extent as in healthy participants. However, for "off" medication, this improvement was associated with increased frequency of anticipation errors, which were eliminated by dopamine replacement. Dopamine replacement had an additional, albeit small effect, on reward-related improvement of movement execution. Motivational strategies are helpful in overcoming bradykinesia in Parkinson's disease. Motivational factors may have a greater effect on bradykinesia when patients are "on" medication, as dopamine appears to be required for overcoming speed-accuracy trade-off and for improvement of movement execution. Thus, medication status should be an important consideration in movement rehabilitation programmes for patients with Parkinson's disease

The spine in Paget’s disease

Paget’s disease (PD) is a chronic metabolically active bone disease, characterized by a disturbance in bone modelling and remodelling due to an increase in osteoblastic and osteoclastic activity. The vertebra is the second most commonly affected site. This article reviews the various spinal pathomechanisms and osseous dynamics involved in producing the varied imaging appearances and their clinical relevance. Advanced imaging of osseous, articular and bone marrow manifestations of PD in all the vertebral components are presented. Pagetic changes often result in clinical symptoms including back pain, spinal stenosis and neural dysfunction. Various pathological complications due to PD involvement result in these clinical symptoms. Recognition of the imaging manifestations of spinal PD and the potential complications that cause the clinical symptoms enables accurate assessment of patients prior to appropriate management

Champs magnétiques 50–60 Hz et santé : quoi de neuf ?

Fin 2013, le SCENIHR (Scientific Comittee on Emerging and Newly Identified Health Risks), a publié un nouveau rapport sur les risques pour la santé liés aux champs électromagnétiques de 0 à 300 GHz. Cette revue de la littérature ne retient pas l’éventualité d’un risque sanitaire lié à l’exposition au champ magnétique extrêmement basse fréquence. À propos des leucémies de l’enfant, le rapport soulève une série de questions cruciales qui méritent une analyse plus fine. La prise en compte de l’exposition demeure le talon d’Achille des études épidémiologiques et aucune d’entre elles n’a apporté de solution cohérente. La question des leucémies de l’enfant est ici analysée à la lumière des dernières études publiées. Compte tenu de la faiblesse et des lacunes dans l’estimation des expositions, de l’hétérogénéité des études incluses et de la diminution de l’odds ratio au cours du temps pour les populations les plus exposées, il n’apparait pas de cohérence entre les résultats des études. Après 30 ans de recherche, deux pistes mériteraient d’être explorées : l’évaluation globale de l’exposition, prenant en compte toutes les sources d’exposition, d’une part et d’autre part la durée d’exposition, non limitée à la moyenne sur 24 h, mais intégrant la durée de résidence de la mère et de l’enfant

Quelle conduite tenir après l’implantation d’un défibrillateur cardiaque chez un travailleur exposé aux champs magnétiques ?

Un défibrillateur automatique implantable (DAI) a été implanté chez un travailleur d’EDF potentiellement exposé à un champ magnétique 50 Hz élevé. Le fonctionnement du DAI peut théoriquement être perturbé par les expositions aux champs magnétiques rencontrées au cours de l’activité professionnelle. À partir de cette étude de cas, nous présentons une approche pour évaluer l’aptitude au travail dans ce type de situation. Le protocole consiste à mesurer le champ magnétique aux différents endroits où le travailleur est susceptible d’aller au cours de son activité professionnelle, et en sa présence, à surveiller en même temps le fonctionnement du DAI. Il s’agissait d’un DAI de marque Medtronic, programmé en mode bipolaire. Dans les différents lieux, le champ magnétique maximum mesuré au niveau du DAI a été de 650 µT. Aucun dysfonctionnement n’a été enregistré en mode bipolaire. Suite à ces mesures et contrôles du DAI, l’agent a été déclaré apte et a repris ses fonctions professionnelles antérieures. Deux ans après, aucun incident n’a été rapporté